Liposome-Based Targeted Drug Delivery for the Treatment of Tuberculosis: A Review

Tuberculosis remains a major cause of infectious mortality, and successful treatment requires effective multidrug exposure across heterogeneous disease sites. Conventional administration is complicated by prolonged therapy, adverse effects, variable pharmacokinetics and incomplete access to some intracellular and tissue compartments. Liposomes provide aqueous and lipid domains capable of accommodating antitubercular drugs with different physicochemical properties. Their composition, size and surface characteristics influence drug retention, biological distribution and interaction with macrophages. This narrative review examines the rationale for liposomal treatment of tuberculosis, with particular attention to isoniazid and rifampicin, vesicle architecture, preparation principles, characterization and research evidence. Selected original studies support sustained drug delivery and improved preclinical performance, while recent co-encapsulation work demonstrates continuing interest in coordinated delivery of complementary agents. Nevertheless, cellular uptake, prolonged release and favourable laboratory findings do not independently establish clinical benefit. Major unresolved issues include access to diverse lesion compartments, maintenance of effective drug combinations, storage stability, reproducible manufacture and route-specific tolerability. Clinical experience with inhaled liposomal amikacin in nontuberculous mycobacterial disease provides a relevant platform precedent but does not demonstrate efficacy against tuberculosis. Liposomes should therefore be regarded as investigational tools for improving antitubercular drug delivery, with their therapeutic value dependent on rigorous pharmacological and clinical validation.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-14
DOI
https://doi.org/10.5281/zenodo.24216854
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Liposome-Based Targeted Drug Delivery for the Treatment of Tuberculosis: A Review

Vishal S. Madankar, Rutuja P. Sonune, Dr. Sampat D. Navale
Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
article

Liposome-Based Targeted Drug Delivery for the Treatment of Tuberculosis: A Review

Vishal S. Madankar, Rutuja P. Sonune, Dr. Sampat D. Navale
article en

Abstract

Tuberculosis remains a major cause of infectious mortality, and successful treatment requires effective multidrug exposure across heterogeneous disease sites. Conventional administration is complicated by prolonged therapy, adverse effects, variable pharmacokinetics and incomplete access to some intracellular and tissue compartments. Liposomes provide aqueous and lipid domains capable of accommodating antitubercular drugs with different physicochemical properties. Their composition, size and surface characteristics influence drug retention, biological distribution and interaction with macrophages. This narrative review examines the rationale for liposomal treatment of tuberculosis, with particular attention to isoniazid and rifampicin, vesicle architecture, preparation principles, characterization and research evidence. Selected original studies support sustained drug delivery and improved preclinical performance, while recent co-encapsulation work demonstrates continuing interest in coordinated delivery of complementary agents. Nevertheless, cellular uptake, prolonged release and favourable laboratory findings do not independently establish clinical benefit. Major unresolved issues include access to diverse lesion compartments, maintenance of effective drug combinations, storage stability, reproducible manufacture and route-specific tolerability. Clinical experience with inhaled liposomal amikacin in nontuberculous mycobacterial disease provides a relevant platform precedent but does not demonstrate efficacy against tuberculosis. Liposomes should therefore be regarded as investigational tools for improving antitubercular drug delivery, with their therapeutic value dependent on rigorous pharmacological and clinical validation.

Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon